Philippe Samama

Title: Philippe Samama: Innovator in Bioconjugate Technology

Introduction

Philippe Samama is a notable inventor based in Lawrenceville, NJ (US). He has made significant contributions to the field of bioconjugate technology, particularly in the development of polypeptides that enhance the understanding of chemokine receptors.

Latest Patents

Samama holds a patent for "Site-specific bioconjugates of chemokines and their use in assays." This invention encompasses polypeptides that include a chemokine receptor binding sequence, which are instrumental in determining the affinity of compounds for chemokine receptors. Notably, the substitution of one of the amino acids in the C-terminal region of the polypeptide with a cysteine allows for detectable labeling without compromising receptor binding activity. This innovation also addresses the challenges associated with radioiodine labeling. Methods for utilizing these polypeptides in competitive binding assays are also disclosed in the patent.

Career Highlights

Philippe Samama has been associated with Pharmacopeia Inc., where he has applied his expertise in bioconjugate technology. His work has contributed to advancements in the field, particularly in the development of assays that utilize his patented polypeptides.

Collaborations

Throughout his career, Samama has collaborated with notable colleagues, including James Inglese and Kenneth C Appell. These collaborations have further enriched his research and development efforts in the bioconjugate domain.

Conclusion

Philippe Samama's innovative work in bioconjugate technology has paved the way for advancements in understanding chemokine receptors. His contributions, particularly through his patent, highlight the importance of his research in the field.